×
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
NASDAQ:GILD

Gilead Sciences Stock Forecast, Price & News

$62.36
+0.55 (+0.89%)
(As of 07/1/2022 08:44 PM ET)
Add
Compare
Today's Range
$61.27
$62.43
50-Day Range
$57.72
$65.01
52-Week Range
$57.17
$74.12
Volume
5.21 million shs
Average Volume
9.67 million shs
Market Capitalization
$78.22 billion
P/E Ratio
17.42
Dividend Yield
4.68%
Price Target
$72.07

Gilead Sciences MarketRank™ Forecast

Analyst Rating
Hold
2.23 Rating Score
Upside/​Downside
15.6% Upside
$72.07 Price Target
Short Interest
Healthy
1.25% of Shares Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-2.24
Upright™ Environmental Score
News Sentiment
0.49mentions of Gilead Sciences in the last 14 days
Based on 15 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
-5.01%
From $6.59 to $6.26 Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

2.77 out of 5 stars

Medical Sector

31st out of 1,412 stocks

Biological Products, Except Diagnostic Industry

2nd out of 215 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive GILD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gilead Sciences and its competitors with MarketBeat's FREE daily newsletter.

Gilead Sciences logo

About Gilead Sciences (NASDAQ:GILD) Stock

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.

GILD Stock News Headlines

Downturn Gives These 3 Buys Juicy Dividend Yields
Simply going after the highest yields isn't a winning strategy. Companies that have the long-term growth prospects to support those dividend payouts are ideal.
Recent Stock Purchase June 2022
The ally
See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:GILD
CUSIP
37555810
Employees
14,400
Year Founded
1987

Company Calendar

Last Earnings
4/28/2022
Ex-Dividend for 6/29 Dividend
6/14/2022
Dividend Payable
6/29/2022
Today
7/03/2022
Next Earnings (Estimated)
8/04/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$72.07
High Stock Price Forecast
$90.00
Low Stock Price Forecast
$56.00
Forecasted Upside/Downside
+15.6%
Consensus Rating
Hold
Rating Score (0-4)
2.23076923076923
Research Coverage
13 Analysts

Profitability

Net Income
$6.23 billion
Pretax Margin
21.34%

Debt

Sales & Book Value

Annual Sales
$27.31 billion
Cash Flow
$8.96 per share
Book Value
$16.79 per share

Miscellaneous

Outstanding Shares
1,254,313,000
Free Float
1,252,306,000
Market Cap
$78.22 billion
Optionable
Optionable
Beta
0.38

Social Links















Gilead Sciences Frequently Asked Questions

Should I buy or sell Gilead Sciences stock right now?

13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Gilead Sciences in the last twelve months. There are currently 1 sell rating, 8 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Gilead Sciences stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GILD, but not buy additional shares or sell existing shares.
View analyst ratings for Gilead Sciences
or view top-rated stocks.

What is Gilead Sciences' stock price forecast for 2022?

13 brokerages have issued 12 month target prices for Gilead Sciences' stock. Their GILD stock forecasts range from $56.00 to $90.00. On average, they predict Gilead Sciences' share price to reach $72.07 in the next year. This suggests a possible upside of 15.6% from the stock's current price.
View analysts' price targets for Gilead Sciences
or view top-rated stocks among Wall Street analysts.

How has Gilead Sciences' stock performed in 2022?

Gilead Sciences' stock was trading at $72.61 on January 1st, 2022. Since then, GILD stock has decreased by 14.1% and is now trading at $62.36.
View the best growth stocks for 2022 here
.

When is Gilead Sciences' next earnings date?

Gilead Sciences is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Gilead Sciences
.

How were Gilead Sciences' earnings last quarter?

Gilead Sciences, Inc. (NASDAQ:GILD) issued its quarterly earnings results on Thursday, April, 28th. The biopharmaceutical company reported $2.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.77 by $0.35. The biopharmaceutical company earned $6.59 billion during the quarter, compared to the consensus estimate of $6.28 billion. Gilead Sciences had a trailing twelve-month return on equity of 44.98% and a net margin of 16.43%. The company's quarterly revenue was up 2.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.08 EPS.
View Gilead Sciences' earnings history
.

How often does Gilead Sciences pay dividends? What is the dividend yield for Gilead Sciences?

Gilead Sciences announced a quarterly dividend on Monday, May 2nd. Investors of record on Wednesday, June 15th will be paid a dividend of $0.73 per share on Wednesday, June 29th. This represents a $2.92 dividend on an annualized basis and a yield of 4.68%. The ex-dividend date of this dividend is Tuesday, June 14th.
View Gilead Sciences' dividend history
.

Is Gilead Sciences a good dividend stock?

Gilead Sciences(NASDAQ:GILD) pays an annual dividend of $2.92 per share and currently has a dividend yield of 4.68%. GILD has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. Gilead Sciences has been increasing its dividend for 7 consecutive years, indicating the company has a new, but growing committment to grow its dividend. The dividend payout ratio of Gilead Sciences is 81.56%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, Gilead Sciences will have a dividend payout ratio of 46.65% next year. This indicates that Gilead Sciences will be able to sustain or increase its dividend.
View Gilead Sciences' dividend history.

What guidance has Gilead Sciences issued on next quarter's earnings?

Gilead Sciences issued an update on its FY 2022 earnings guidance on Monday, May, 9th. The company provided earnings per share (EPS) guidance of $6.20-$6.70 for the period, compared to the consensus earnings per share estimate of $6.50. The company issued revenue guidance of $23.80 billion-$24.30 billion, compared to the consensus revenue estimate of $24.48 billion.

Who are Gilead Sciences' key executives?

Gilead Sciences' management team includes the following people:
  • Mr. Daniel P. O'Day, Chairman & CEO (Age 58, Pay $6.09M)
  • Mr. Andrew D. Dickinson, Exec. VP & CFO (Age 52, Pay $2.55M)
  • Mr. Brett A. Pletcher, Exec. VP of Corp. Affairs, Gen. Counsel & Corp. Sec. (Age 53, Pay $2.47M) (LinkedIn Profile)
  • Ms. Johanna Mercier, Chief Commercial Officer (Age 52, Pay $2.92M) (LinkedIn Profile)
  • Dr. Merdad V. Parsey M.D., Ph.D., Chief Medical Officer (Age 59, Pay $2.68M)
  • Ms. Diane E. Wilfong, Sr. VP, Corp. Controller & Chief Accounting Officer (Age 60) (LinkedIn Profile)
  • Ms. Jacquie Ross C.F.A., VP of Investor Relations
  • Ms. Jyoti K. Mehra, Exec. VP of HR
  • Dr. Taiyin Yang Ph.D., Exec. VP of Pharmaceutical Devel. & Manufacturing (Age 68)
  • Dr. Michael Quigley Ph.D., Sr. VP of Research Biology

What is Daniel O’Day's approval rating as Gilead Sciences' CEO?

107 employees have rated Gilead Sciences CEO Daniel O’Day on Glassdoor.com. Daniel O’Day has an approval rating of 92% among Gilead Sciences' employees. This puts Daniel O’Day in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Gilead Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Gilead Sciences investors own include NVIDIA (NVDA), Walt Disney (DIS), Micron Technology (MU), Intel (INTC), Alibaba Group (BABA), Pfizer (PFE), Tesla (TSLA), AbbVie (ABBV), Netflix (NFLX) and Johnson & Johnson (JNJ).

What is Gilead Sciences' stock symbol?

Gilead Sciences trades on the NASDAQ under the ticker symbol "GILD."

Who are Gilead Sciences' major shareholders?

Gilead Sciences' stock is owned by a variety of retail and institutional investors. Top institutional investors include First Financial Bank Trust Division (0.01%) and Insight Wealth Strategies LLC (0.00%). Company insiders that own Gilead Sciences stock include Brett A Pletcher, Diane E Wilfong, Diane E Wilfong, Gayle E Wilson, Javier Rodriguez, Johanna Mercier, John Francis Cogan, Merdad Parsey, Olsen Per Wold and Richard James Whitley.
View institutional ownership trends for Gilead Sciences
.

Which major investors are buying Gilead Sciences stock?

GILD stock was acquired by a variety of institutional investors in the last quarter, including Insight Wealth Strategies LLC, and First Financial Bank Trust Division.
View insider buying and selling activity for Gilead Sciences
or or view top insider-buying stocks.

How do I buy shares of Gilead Sciences?

Shares of GILD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Gilead Sciences' stock price today?

One share of GILD stock can currently be purchased for approximately $62.36.

How much money does Gilead Sciences make?

Gilead Sciences (NASDAQ:GILD) has a market capitalization of $78.22 billion and generates $27.31 billion in revenue each year. The biopharmaceutical company earns $6.23 billion in net income (profit) each year or $3.579990 on an earnings per share basis.

How many employees does Gilead Sciences have?

Gilead Sciences employs 14,400 workers across the globe.

Does Gilead Sciences have any subsidiaries?

The following companies are subsidiares of Gilead Sciences: Arresto BioSciences, Asegua Therapeutics LLC, CGI Pharmaceuticals, CV Therapeutics, Calistoga Pharmaceuticals, Cell Design Labs, Corus Pharma, Cytopia Pty. Ltd., EpiTherapeutics ApS, Epitherapeutics, Forty Seven, Forty Seven Holdings LLC, Forty Seven Inc., Fosun Pharma Kite Biotechnology Co. Ltd., Gilead Alberta LLC, Gilead Alberta ULC, Gilead Apollo LLC, Gilead Apollo Unlimited Company, Gilead Biopharmaceutics Ireland UC, Gilead Biopharmaceutics US LLC, Gilead Calistoga LLC, Gilead Connecticut Inc., Gilead Holdings LLC, Gilead Ireland Research UC, Gilead Oncology Ireland UC, Gilead Pharmasset LLC, Gilead Sciences (GSR) S.R.L., Gilead Sciences (NZ), Gilead Sciences (Shanghai) Consulting Co. Ltd., Gilead Sciences Americas S. de R.L., Gilead Sciences Argentina S.R.L., Gilead Sciences Belgium BVBA, Gilead Sciences Canada Inc., Gilead Sciences Colombia S.A.S., Gilead Sciences Denmark ApS, Gilead Sciences Europe Limited, Gilead Sciences Farmacêutica do Brasil Ltda., Gilead Sciences Finland Oy, Gilead Sciences GesmbH., Gilead Sciences GmbH, Gilead Sciences Hangzhou Pharmaceutical Co. Ltd., Gilead Sciences Hellas EPE, Gilead Sciences Holding LLC, Gilead Sciences Hong Kong Limited, Gilead Sciences Ilac Ticaret Limited Sirketi, Gilead Sciences India Private Limited, Gilead Sciences International Limited, Gilead Sciences Ireland Unlimited Company, Gilead Sciences Israel Limited, Gilead Sciences KK, Gilead Sciences Korea Limited, Gilead Sciences LLC, Gilead Sciences Lda., Gilead Sciences Limited, Gilead Sciences Luxembourg S.a.r.l., Gilead Sciences Malaysia Sdn. Bhd., Gilead Sciences Mexico S. de R.L. de C.V., Gilead Sciences Netherlands BV, Gilead Sciences Norway AS, Gilead Sciences Poland Sp. z o.o., Gilead Sciences Pty. Ltd., Gilead Sciences Russia LLC, Gilead Sciences S.L., Gilead Sciences S.r.l., Gilead Sciences SAS, Gilead Sciences Shanghai Pharmaceutical Technology Co. Ltd., Gilead Sciences Singapore Pte. Ltd., Gilead Sciences Slovakia s.r.o., Gilead Sciences South Africa (Pty) Ltd., Gilead Sciences Sweden AB, Gilead Sciences Switzerland Sarl, Gilead Sciences YM Australia Pty. Ltd., Gilead Sciences s.r.o., Gilead Therapeutics A1 Unlimited Company, Gilead Therapeutics A2 Unlimited Company, Gilead YM ULC, Immunomedics, Immunomedics Inc., KP EU C.V., Kite Pharma, Kite Pharma EU B.V., Kite Pharma Inc., Kite Pharma LLC, MYR, MYR GmbH, MYR Pharmaceuticals France SAS, Myogen, NeXstar Pharmaceuticals, Nimbus Apollo, Nycomed, Pharmasset, Phenex Pharmaceuticals, Raylo Chemicals, Triangle Pharmaceuticals, YM BioSciences, YM BioSciences Australia Pty. Ltd., and neoKite Inc..
Read More

When was Gilead Sciences founded?

Gilead Sciences was founded in 1987.

How can I contact Gilead Sciences?

Gilead Sciences' mailing address is 333 LAKESIDE DRIVE, FOSTER CITY CA, 94404. The official website for Gilead Sciences is www.gilead.com. The biopharmaceutical company can be reached via phone at (650) 574-3000, via email at investor_relations@gilead.com, or via fax at 650-578-9264.

This page (NASDAQ:GILD) was last updated on 7/4/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.